FDA must rewrite rules to formally allow non-animal drug testing methods

What does this do?

HR 2821 requires the FDA to rewrite specific regulations within one year, replacing outdated "animal" testing language with the broader term "nonclinical testing." This aligns the FDA's actual rules with a 2022 law that already allows drug companies to use alternatives like lab-grown tissue models, organ-on-a-chip technology, or computer simulations. The bill also lets the FDA skip some standard public-comment procedures so the update can take effect immediately, and fixes a duplicate section label from prior law.

Who does it affect?

Pharmaceutical and biotech companies developing new drugs, plus researchers working on alternative testing methods, are directly affected. Patients could be indirectly affected through changes in how drug development timelines and testing options play out.

Why does it matter?

The mismatch between the 2022 law and outdated FDA regulations has created confusion over whether non-animal testing methods are truly permitted. Updating the rules removes that legal ambiguity and may also reduce the number of animals used in laboratory research.

Where does it stand?